Krystal Biotech (KRYS) Accounts Payables (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Accounts Payables data on file, last reported at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 53.03% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 53.03% YoY), and the FY2025 full-year result was $3.2 million, down 35.05% from the prior year.
• Accounts Payables improved to $4.1 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $9.2 million in Q2 2022 to a low of $2.1 million in Q3 2025.
• A 5-year average of $5.0 million and a median of $4.4 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 629.57% in 2022 and sank 62.42% in 2025, its largest moves.
• Tracing KRYS's Accounts Payables over 5 years: stood at $4.0 million in 2022, then climbed by 3.79% to $4.1 million in 2023, then advanced by 20.64% to $5.0 million in 2024, then sank by 35.05% to $3.2 million in 2025, then grew by 26.28% to $4.1 million in 2026.
• Business Quant data shows KRYS's Accounts Payables at $4.1 million in Q1 2026, $3.2 million in Q4 2025, and $2.1 million in Q3 2025.